Cambium Bio Limited (CMB.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 7 | 0 | 0 | 0 | 1 | - | 1 | 1 |
| Operating profit | AUD m | -4 | -4 | ||||||
| Net profit | AUD m | 3 | -4 | -3 | -2 | -4 | - | -4 | - |
| EPS reported | AUD | -0.21 | -0.17 | ||||||
| Operating cashflow per share | AUD | -0.29 | -0.11 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.29 | -0.11 | ||||||
| Free cash flow | AUD m | -5 | -3 | ||||||
| Net debt | AUD m | 0 | -1 | ||||||
| Book value equity | AUD m | 2 | 2 | ||||||
| Book value per share | AUD | 0.10 | 0.09 | ||||||
| Number of shares | m | 18.28 | 25.41 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.91 | 1.61 | ||||||
| P/S LTM | x | 2.49 | 5.98 | ||||||
| P/FCF LTM | x | -0.32 | -1.37 | ||||||
| EV/EBITDA LTM | x | 0.19 | -0.95 | ||||||
| EV/Sales LTM | x | 6.20 | 19.59 | ||||||
| Earnings Yield LTM | % | -1.00% | -35.05% | ||||||
| FCF Yield | % | -314.50% | -73.18% | ||||||
| Quality | |||||||||
| ROE | % | -209.41% | -164.96% | ||||||
| ROIC | % | -1.80% | -1.51% | ||||||
| Operating margin | % | -6.41% | -6.79% | ||||||
| Gross margin | % | +69.30% | +70.34% | ||||||
| FCF/Sales | % | -783.11% | -437.92% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | -4.24% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.87 | -18.76 | ||||||
| Net Debt/EBITDA | x | -0.08 | 0.22 | ||||||
| EBIT/Net interest | x | -122.80 | -256.63 | ||||||
| Net debt/market cap | % | +12.57% | +1.11% | ||||||
| Net debt/Equity | x | 0.17 | -0.41 | ||||||
| Gross debt/equity | x | 0.26 | 0.06 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free